<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1219">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04841707</url>
  </required_header>
  <id_info>
    <org_study_id>1697954</org_study_id>
    <nct_id>NCT04841707</nct_id>
  </id_info>
  <brief_title>Total-Body Parametric 18F-FDG PET of COVID-19</brief_title>
  <official_title>Total-Body Parametric 18F-FDG PET of COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to measure the change between COVID-19 patients and normal subjects;&#xD;
      the secondary objective is to measure the change in COVID-19 patients between baseline and&#xD;
      4-month follow up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 22, 2021</start_date>
  <completion_date type="Anticipated">February 22, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 22, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BAB permeability assessed</measure>
    <time_frame>1 imaging visit up to 60 minutes</time_frame>
    <description>Evaluating if there is a change in BAB permeability assessed by lung FDG K1 for patients with COVID 19</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>4 month follow-up PET/CT scan</measure>
    <time_frame>1 imaging visit up to 60 minutes</time_frame>
    <description>Evaluate the change in the scans between baseline scan and 4-month follow-up scan by assessing the pulmonary blood-air barrier permeability to glucose</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>COVID-19 patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>uEXPLORER/mCT</intervention_name>
    <description>Each participant will undergo two 18F-FDG PET/CT scans, one at baseline and one at 4- month (+/- 2 weeks) follow-up.</description>
    <arm_group_label>COVID-19 patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COVID-19 positive patients will have a previous positive COVID-19 test and&#xD;
             radiographic findings, and/or a positive SARS-CoV-2 antibody test and be in early&#xD;
             recovery.&#xD;
&#xD;
          -  First PET/CT visit needs to be within 8 weeks of COVID-19 diagnosis.&#xD;
&#xD;
          -  Ability to understand and willingness to sign an informed consent form.&#xD;
&#xD;
          -  Ability to adhere to the study visit schedule and other protocol requirements.&#xD;
&#xD;
          -  All persons â‰¥18 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Any condition that would prohibit the understanding or rendering of informed consent.&#xD;
&#xD;
          -  Unable to lie supine for 1-hour imaging with PET.&#xD;
&#xD;
          -  Prisoners.&#xD;
&#xD;
          -  Any comorbidity that, in the opinion of the investigator, could compromise protocol&#xD;
             objectives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guobao Wang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynda Painting</last_name>
    <phone>916-731-9004</phone>
    <email>lpainting@ucdavis.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dana Little, MS</last_name>
    <phone>916-734-7749</phone>
    <email>dalittle@ucdavis.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynda Painting, BS</last_name>
      <phone>916-731-9004</phone>
      <email>lpainting@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dana Little, MS</last_name>
      <phone>916-734-7749</phone>
      <email>dalittle@ucdavis.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

